生物
癌症研究
突变
乳腺癌
卵泡期
癌症
免疫学
细胞生物学
遗传学
基因
作者
Daniel P. Hollern,Nuo Xu,Aatish Thennavan,Cherise Ryan Glodowski,Susana García‐Recio,Kevin R. Mott,Xiaping He,Joseph P. Garay,Kelly Carey-Ewend,David Marron,John Ford,Siyao Liu,Sarah C. Vick,Miguel Martín,Joel S. Parker,Benjamin G. Vincent,Jonathan S. Serody,Charles M. Perou
出处
期刊:Cell
[Cell Press]
日期:2019-11-01
卷期号:179 (5): 1191-1206.e21
被引量:393
标识
DOI:10.1016/j.cell.2019.10.028
摘要
This study identifies mechanisms mediating responses to immune checkpoint inhibitors using mouse models of triple-negative breast cancer. By creating new mammary tumor models, we find that tumor mutation burden and specific immune cells are associated with response. Further, we developed a rich resource of single-cell RNA-seq and bulk mRNA-seq data of immunotherapy-treated and non-treated tumors from sensitive and resistant murine models. Using this, we uncover that immune checkpoint therapy induces T follicular helper cell activation of B cells to facilitate the anti-tumor response in these models. We also show that B cell activation of T cells and the generation of antibody are key to immunotherapy response and propose a new biomarker for immune checkpoint therapy. In total, this work presents resources of new preclinical models of breast cancer with large mRNA-seq and single-cell RNA-seq datasets annotated for sensitivity to therapy and uncovers new components of response to immune checkpoint inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI